Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001342 | 0.84 | MAPK1 (0.55) | MAPK1NR1I2LMNAHTTRORC | |
| SCHEMBL3821934 | 0.84 | VCAM1 (0.54) | MAPK1LMNAHTTVCAM1MEN1 | |
| SCHEMBL3181705 | 0.82 | VCAM1 (0.52) | MAPK1LMNAHTTVCAM1ALDH1A1 | |
| SCHEMBL3153575 | 0.82 | VCAM1 (0.52) | MAPK1LMNAHTTVCAM1ALDH1A1 | |
| SCHEMBL6749735 | 0.82 | VCAM1 (0.49) | MAPK1NR1I2LMNAHTTVCAM1 | |
| SCHEMBL17230528 | 0.82 | VCAM1 (0.52) | MAPK1LMNAHTTVCAM1ALDH1A1 | |
| SCHEMBL17230532 | 0.82 | BMP1 (0.55) | LMNAHTTVCAM1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6122525 | 0.81 | KMT2A (0.56) | MAPK1MEN1KMT2A | |
| SCHEMBL7757753 | 0.81 | MAPK1 (0.49) | MAPK1NR1I2LMNAHTTKMT2A | |
| SCHEMBL18997833 | 0.81 | MAPK1 (0.52) | MAPK1NR1I2LMNAHTTRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575205-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8263808-B2 | Method for deprotecting aryl or alkyl sulfonamides of primary or secondary amines | SIGNA CHEMISTRY, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263808-B2 | Method for deprotecting aryl or alkyl sulfonamides of primary or secondary amines | SIGNA CHEMISTRY, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | NITZ THEODORE J (US) | 2012-07-19 | — | — | US | disclosed |
| US-8202896-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20090306391-A1 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | SIGNA CHEMISTRY, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306391-A1 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | SIGNA CHEMISTRY, LLC (US) | 2009-12-10 | — | — | US | disclosed |
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288344-A1 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | TTPA, HAVCR2, ZC3HAV1 | MAPK1 4276/4885NR1I2 1869/4885LMNA 254/4885 |
| US-20090306391-A1 | METHOD FOR DEPROTECTING ARYL OR ALKYL SULFONAMIDES OF PRIMARY OR SECONDARY AMINES | ARSA, KCNJ1, SIK3 | MAPK1 1261/4885NR1I2 3407/4885LMNA 537/4885 |
| US-20120183498-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, ZC3HAV1 | MAPK1 4276/4885NR1I2 1869/4885LMNA 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.